Pricing Log in Create free account
Friday 6 November 2026 Export GYRE’s income statement to Excel — free account

Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

Revenue
+7.75%
EPS
−200.0%
Free cash flow
−129.9%

Quarter to September 2026, against a year earlier

4.72 0.71 +17.71%
Market cap
$425.2M
P/E
0.0×
Fwd P/E
−11.4×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.95
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 5 4 — — — — —
Insider Ownership 77.75%

Capital & Financial Ratios $m

Size
Market Cap 425.20
Revenue ttm 121.75
Net income ttm (27.97)
Free cash flow ttm (24.28)
Net debt Q (74.80)
Valuation
P/E 0.00
Forward P/E (11.40) (negative: loss-making)
Price / sales 4.12
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.47
Financial health
Current ratio Q 4.32 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (15.23)
Growth
Revenue growth Q +7.75% (above 0%: growing)
Operating income growth Q −541.21% (below 0%: shrinking)
EPS, this year −2,100.00% (below 0%: weak)
EPS, next year A +41.25% (at or above 15%: strong)
Revenue, next year A −6.08% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +21.64% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.5×, against a ten-year median of 2.1×; over the ten years it ranged from −44.5× in 2018 to 156× in 2018.
P/S against its own 10 years 14.33%
10-year low 10-year high
P/B against its own 10 years 70.82%
10-year low 10-year high
EV/Sales against its own 10 years 28.16%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 34 27 52 —
Receivables 16 25 31 —
Inventory 4 6 10 12
Other 1 1 1 —
57 65 102 123
2023 2024 2025 Q'26
Payables 0 0 0 3
ST’ Debt — — — —
Other 0 5 0 —
20 20 18 29

Compound Annual Growth %

10y 5y 3y
Sales 51.64% 40.96% 4.46%
Cash Flow 0.00% 0.00% (54.44%)
Earnings 0.00% 0.00% 29.74%
Book Value 16.30% 13.34% 25.36%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.08 Actual −0.12

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.05 0.06 Beat by 0.01
Q4 FY25 0.08 0.04 Miss by 0.04
Q1 FY26 −0.06 −0.05 Beat by 0.01
Q2 FY26 −0.08 −0.12 Miss by 0.04
Q3 FY26 −0.15 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.12) (0.04) — —
’25 0.00 0.01 0.03 (0.02) 0.02
’24 0.03 0.01 0.01 0.00 0.05
’23 0.15 (1.05) 0.05 (1.49) (1.41)
’22 (6.90) 24.59 (2.40) (19.19) (3.90)
’21 (11.84) (9.60) (11.99) (9.60) (43.03)
’20 (4.20) (14.39) (10.94) (12.89) (43.93)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 23 29 33 — —
’25 22 27 31 37 117
’24 27 25 25 28 106
’23 25 29 32 27 113
’22 1 — — 101 102
’21 1 1 2 2 7
’20 16 2 1 2 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (17) (4) — —
’25 0 (7) 14 (6) 1
’24 3 (5) 2 (3) (4)
’23 10 5 8 3 26
’22 (12) (12) (7) 42 11
’21 (24) (20) (22) (18) (84)
’20 (5) (15) (13) (22) (55)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (18) (4) — —
’25 (1) (8) 14 (6) (1)
’24 3 (7) 1 (3) (6)
’23 9 2 6 1 18
’22 (12) (12) (7) 37 6
’21 (24) (20) (22) (18) (85)
’20 (5) (15) (13) (22) (55)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 1 0 — 21 7 102 113 106 117 122 +87.9% 110 140 436 +55.3%
Gross margin, % 100.00 100.00 100.00 0.00 56.26 (0.57) 95.31 95.91 96.33 95.35 91.71 (4.6) pt
EBT (17) (22) (30) (55) (56) (88) 9 (77) 23 14 (22) n/m
EBT margin, % (4,246.87) (2,117.98) (500,916.67) 0.00 (268.48) (1,198.32) 9.20 (67.84) 21.95 12.38 (17.80) +4,259.3 pt
Net income (17) (22) (30) (55) (56) (88) 4 (85) 18 10 (28) n/m
Per share, $
Per share, $ Revenue 7.67 4.46 0.01 0.00 16.38 3.59 1.61 1.72 1.24 1.30 1.15 (17.9%)
Earnings (326.09) (111.69) (40.18) (68.97) (43.93) (43.03) (3.90) (1.41) 0.14 0.06 (0.28) n/m
Cash flow (355.23) (87.30) (38.17) (54.47) (43.03) (40.98) 0.17 0.39 (0.04) 0.01 (0.22) n/m
Capex 40.31 (0.10) (0.50) (0.08) (0.21) (0.41) (0.08) (0.12) (0.03) (0.02) (0.01) n/m
Free cash flow (314.92) (87.40) (38.68) (54.55) (43.24) (41.39) 0.09 0.27 (0.07) (0.01) (0.23) (68.4%)
Book value 309.06 134.74 160.35 85.35 59.47 20.10 1.14 1.19 1.16 1.59 0.00 (44.3%)
Shares, m 0 0 1 1 1 2 64 66 85 89 97 +128.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 86.43 128.36 0.00 23.9
P/S 19.34 48.36 117.55 — 5.78 3.82 5.21 13.80 9.74 5.41 4.12 25.4
P/B 0.48 1.60 0.74 — 1.59 0.68 7.72 112.28 10.46 10.59 3.47 16.2
EV/Sales (23.24) 16.39 (35.10) — 2.24 (1.85) 5.02 13.56 9.53 4.66 3.55 (1.0)
EV/FCF 0.57 (0.84) 0.91 — (0.85) 0.16 94.47 85.58 (158.25) (615.37) (17.00) (66.0)
Cash, $m
Cash, $m Operating cash flow (18) (20) (29) (44) (55) (84) 11 26 (4) 1 (23) n/m
Capex 2 0 0 0 0 (1) (5) (8) (3) (2) (1) n/m
Free cash flow (16) (20) (29) (44) (55) (85) 6 18 (6) (1) (24) (27.7%)
Balance, $m
Balance, $m Working capital 16 30 119 67 72 37 37 37 45 84 95 +20.6%
Net debt (17) (33) (120) (77) (79) (47) (25) (34) (27) (52) (75) +13.2%
Shareholders’ equity 16 31 120 68 76 41 72 78 98 142 165 +27.4%
Returns, %
Returns, % ROA (31.49) (65.75) (36.56) (49.38) (58.16) (116.85) 3.28 (92.34) 9.99 3.45 (14.49) +34.9 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 12.23 (93.45) 14.08 7.99 (8.51) +8.0 pt
ROE (71.35) (108.92) (39.88) (58.61) (77.89) (150.11) 4.06 (215.71) 21.51 4.18 (18.54) +75.5 pt
People
People Employees 10 13 21 34 56 45 7 593 579 625 — +58.3%
Revenue/emp, $m 0.04 0.08 0.00 0.00 0.37 0.16 14.61 0.19 0.18 0.19 — +18.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Gyre Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EPRX Eupraxia Pharmaceuticals Inc. $429.1M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
ARVN Arvinas, Inc. $428.9M — (loss-making) — (loss-making) −98.81% (below 0%: shrinking) n/m +82.77% (above 0%: growing) 80.00% (11,820.00%) Compare
GYRE Gyre Therapeutics, Inc. $425.2M — (loss-making) — (loss-making) +7.75% (above 0%: growing) n/m −129.91% (below 0%: shrinking) 94.09% 0.00%
PRTCY PureTech Health PLC Sponsored ADR $424.0M — (loss-making) — (loss-making) −44.60% (below 0%: shrinking) +66.43% (above 0%: growing) +19.27% (above 0%: growing) 2.83% 0.00% Compare
OCS Oculis Holding AG $421.6M — (loss-making) — (loss-making) −97.17% (below 0%: shrinking) n/m −20.85% (below 0%: shrinking) 100.00% (338,436.05%) Compare
PHAT Phathom Pharmaceuticals, Inc. $413.0M — (loss-making) — (loss-making) +71.14% (above 0%: growing) n/m +112.23% (above 0%: growing) 78.32% (0.10%) Compare
CRMD CorMedix Inc $407.6M 2.2× 11.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
ASMB Assembly Biosciences, Inc. $407.2M — (loss-making) — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%) Compare
PRTA Prothena Corporation plc $405.1M — (loss-making) 71.4× −74.33% (below 0%: shrinking) n/m +70.34% (above 0%: growing) 100.00% (3,035.65%) Compare
Median of peers $417.3M — — −44.60% — +44.81% 80.00% (23.77%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 9.50%
Entitles affiliated with GNI Japan 75.20%
Ying Luo, Ph.D. 8.30%
Songjiang Ma 7.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Gyre Therapeutics, Inc. (GYRE) Latest News

5 Nov

Impact 3 · · GlobeNewswire

7 Aug

Impact 3 ·

12 May

Impact 4 · · GlobeNewswire

7 May

Impact 4 · · GlobeNewswire
Impact 3 ·

4 May

Impact 4 · · GlobeNewswire

17 Mar

Impact 4 · · GlobeNewswire

12 Mar

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

3 Mar

Impact 4 · · TipRanks

2 Mar

Impact 4 · · GlobeNewswire

11 Feb

Impact 4 ·

26 Jan

Impact 4 · · Simply Wall St.

13 Jan

Impact 4 · · Simply Wall St.

5 Jan

Impact 4 · · GlobeNewswire

26 Dec

Impact 4 · · Simply Wall St.

15 Dec

Impact 3 · · Simply Wall St.

14 Nov

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

11 Nov

Impact 4 · · Simply Wall St.

10 Nov

Impact 3 · · Simply Wall St.

7 Nov

Impact 4 · · Zacks
Impact 3 ·

17 Oct

Impact 4 · · Zacks

15 Oct

Impact 4 · · GlobeNewswireClinical Trials ArenaZacks

14 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire

30 Sep

Impact 4 · · Simply Wall St.

5 Sep

Impact 3 · · GlobeNewswireGlobeNewswireGlobeNewswireGlobeNewswire

22 Aug

Impact 3 ·
stockrow.com/GYRE · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com